A practical guide to managing cardiopulmonary toxicities of tyrosine kinase inhibitors in chronic myeloid leukemia

Tyrosine kinase inhibitors (TKIs) have revolutionized the treatment of chronic myeloid leukemia (CML) but their use was associated with a range of serious cardiopulmonary toxicities including vascular adverse events, QT prolongation, heart failure, pleural effusion, and pulmonary arterial hypertensi...

Descripción completa

Detalles Bibliográficos
Autores principales: Kaddoura, Rasha, Dabdoob, Wafer A., Ahmed, Khalid, Yassin, Mohamed A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10286131/
https://www.ncbi.nlm.nih.gov/pubmed/37358999
http://dx.doi.org/10.3389/fmed.2023.1163137
_version_ 1785061685483012096
author Kaddoura, Rasha
Dabdoob, Wafer A.
Ahmed, Khalid
Yassin, Mohamed A.
author_facet Kaddoura, Rasha
Dabdoob, Wafer A.
Ahmed, Khalid
Yassin, Mohamed A.
author_sort Kaddoura, Rasha
collection PubMed
description Tyrosine kinase inhibitors (TKIs) have revolutionized the treatment of chronic myeloid leukemia (CML) but their use was associated with a range of serious cardiopulmonary toxicities including vascular adverse events, QT prolongation, heart failure, pleural effusion, and pulmonary arterial hypertension. Dedicated clinical management guidelines for TKI-induced toxicities are not available. This review aims to discuss TKI-associated cardiopulmonary toxicities and proposes a practical guide for their management.
format Online
Article
Text
id pubmed-10286131
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-102861312023-06-23 A practical guide to managing cardiopulmonary toxicities of tyrosine kinase inhibitors in chronic myeloid leukemia Kaddoura, Rasha Dabdoob, Wafer A. Ahmed, Khalid Yassin, Mohamed A. Front Med (Lausanne) Medicine Tyrosine kinase inhibitors (TKIs) have revolutionized the treatment of chronic myeloid leukemia (CML) but their use was associated with a range of serious cardiopulmonary toxicities including vascular adverse events, QT prolongation, heart failure, pleural effusion, and pulmonary arterial hypertension. Dedicated clinical management guidelines for TKI-induced toxicities are not available. This review aims to discuss TKI-associated cardiopulmonary toxicities and proposes a practical guide for their management. Frontiers Media S.A. 2023-05-05 /pmc/articles/PMC10286131/ /pubmed/37358999 http://dx.doi.org/10.3389/fmed.2023.1163137 Text en Copyright © 2023 Kaddoura, Dabdoob, Ahmed and Yassin. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Medicine
Kaddoura, Rasha
Dabdoob, Wafer A.
Ahmed, Khalid
Yassin, Mohamed A.
A practical guide to managing cardiopulmonary toxicities of tyrosine kinase inhibitors in chronic myeloid leukemia
title A practical guide to managing cardiopulmonary toxicities of tyrosine kinase inhibitors in chronic myeloid leukemia
title_full A practical guide to managing cardiopulmonary toxicities of tyrosine kinase inhibitors in chronic myeloid leukemia
title_fullStr A practical guide to managing cardiopulmonary toxicities of tyrosine kinase inhibitors in chronic myeloid leukemia
title_full_unstemmed A practical guide to managing cardiopulmonary toxicities of tyrosine kinase inhibitors in chronic myeloid leukemia
title_short A practical guide to managing cardiopulmonary toxicities of tyrosine kinase inhibitors in chronic myeloid leukemia
title_sort practical guide to managing cardiopulmonary toxicities of tyrosine kinase inhibitors in chronic myeloid leukemia
topic Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10286131/
https://www.ncbi.nlm.nih.gov/pubmed/37358999
http://dx.doi.org/10.3389/fmed.2023.1163137
work_keys_str_mv AT kaddourarasha apracticalguidetomanagingcardiopulmonarytoxicitiesoftyrosinekinaseinhibitorsinchronicmyeloidleukemia
AT dabdoobwafera apracticalguidetomanagingcardiopulmonarytoxicitiesoftyrosinekinaseinhibitorsinchronicmyeloidleukemia
AT ahmedkhalid apracticalguidetomanagingcardiopulmonarytoxicitiesoftyrosinekinaseinhibitorsinchronicmyeloidleukemia
AT yassinmohameda apracticalguidetomanagingcardiopulmonarytoxicitiesoftyrosinekinaseinhibitorsinchronicmyeloidleukemia
AT kaddourarasha practicalguidetomanagingcardiopulmonarytoxicitiesoftyrosinekinaseinhibitorsinchronicmyeloidleukemia
AT dabdoobwafera practicalguidetomanagingcardiopulmonarytoxicitiesoftyrosinekinaseinhibitorsinchronicmyeloidleukemia
AT ahmedkhalid practicalguidetomanagingcardiopulmonarytoxicitiesoftyrosinekinaseinhibitorsinchronicmyeloidleukemia
AT yassinmohameda practicalguidetomanagingcardiopulmonarytoxicitiesoftyrosinekinaseinhibitorsinchronicmyeloidleukemia

Ejemplares similares